Bart Wuurman

As multiple entrepreneur and pharmaceutical scientist, Bart Wuurman has been instrumental to the success of everal biotech companies, including Lanthio Pharma and AM-Pharma in The Netherlands and Antisoma in the United Kingdom. He was involved with raising approximately € 80 million in equity funding. Before becoming CEO, Bart was VP Business Development and Licensing for Antisoma plc and Medeva plc in the United Kingdom, where he was responsible for out-licensing deals worth over €700 million.